Switch to:

Adaptive Biotechnologies Cash-to-Debt

: 12.47 (As of Jun. 2020)
View and export this data going back to 2019. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Adaptive Biotechnologies's cash to debt ratio for the quarter that ended in Jun. 2020 was 12.47.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Adaptive Biotechnologies could pay off its debt using the cash in hand for the quarter that ended in Jun. 2020.

NAS:ADPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.47   Med: 5012.23   Max: No Debt
Current: 12.47

12.47
No Debt

During the past 3 years, Adaptive Biotechnologies's highest Cash to Debt Ratio was No Debt. The lowest was 12.47. And the median was 5012.23.

NAS:ADPT's Cash-to-Debt is ranked higher than
56% of the 1243 Companies
in the Biotechnology industry.

( Industry Median: 8.31 vs. NAS:ADPT: 12.47 )

Adaptive Biotechnologies Cash-to-Debt Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Adaptive Biotechnologies Annual Data
Dec17 Dec18 Dec19
Cash-to-Debt No Debt No Debt 15.76

Adaptive Biotechnologies Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt 24.45 15.76 14.59 12.47

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Adaptive Biotechnologies Cash-to-Debt Distribution

* The bar in red indicates where Adaptive Biotechnologies's Cash-to-Debt falls into.



Adaptive Biotechnologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Adaptive Biotechnologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Adaptive Biotechnologies's Cash to Debt Ratio for the quarter that ended in Jun. 2020 is calculated as:

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Adaptive Biotechnologies  (NAS:ADPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Adaptive Biotechnologies Cash-to-Debt Related Terms


Adaptive Biotechnologies Cash-to-Debt Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)